To evaluate in vitro activity of ceftobiprole against clinical isolated bacteria in recent years in China.

The minimal inhibitory concentrations (MICs) were determined by the microbroth dilution method.

A total of 948 clinical isolates collected from nationwide between 2019 to 2020 were studied. Ceftobiprole exhibited excellent antibacterial activity against gram-positive cocci, the value of MIC₉₀ was 0.5 mg·L^-1 for methicillin susceptible Staphylococcus spp and susceptibility rates of methicillin resistant Staphylococcus aureus (MRSA) were 93.1%, which was better than that of ceftaroline (72.3%). The MIC values of ceftobiprole against penicillin nonsusceptible Streptococcus pneumoniae (PNSSP) ranged from 0.06 to 1 mg·L^-1, with 80.0% susceptibility rate . The values of MIC₉₀ of ceftobiprole were ≤2 mg·L^-1 for other streptococci and Enterococcus faecalis. Against Gram-negative bacteria, ceftobiprole also showed better antibacterial activity against non-extended spectrum β-lactamases (ESBLs) Escherichia coli, non-ESBLs Klebsiella pneumoniae, ampicillin-susceptible Haemophilus influenzae and Moraxella catarrhalis, the values of MIC₉₀ ≤0.5 mg·L^-1 and susceptible strains more than 98.1%. The activity of ceftobiprole against Pseudomonas aeruginosa was similar to that of ceftazidime and cefepime.

Ceftobiprole showed excellent antibacterial activity against clinical isolates, include MRSA, PNSSP, and Haemophilus influenzae in recent years in China, which similar to the surveillance results in Europe and America. The clinical prospect is worthy of expectation.